drugset / Trial / NCT06465108
Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.
Timeline
- Start
- 2024-08-08
- Primary completion
- 2025-05-23
- Completion
- 2025-06-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Canvuparatide | Protein / enzyme biologic | 400 ug | Subcutaneous |
| Subject | Canvuparatide | Protein / enzyme biologic | 600 ug | Subcutaneous |
| Subject | Canvuparatide | Protein / enzyme biologic | 800 ug | Subcutaneous |